Zevra Therapeutics Inc
ZVRAHealthcare|Biotechnology|USA
$13.34
-0.59 (-4.23%)
Tangible Book
$3.30
Clinical Trials (5)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06773026 Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Pediatric and Adults Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD) | Medium-chain Acyl-CoA Dehydrogenase Deficiency | P2 | Recruiting | 24 | Open-label | Sodium phenylbutyrate |
| NCT03292952 KP415 Classroom Study in Children (6-12 Years of Age) With ADHD | ADHD | P3 | Completed | 155 | RCT, Double-blind | KP415 oral capsule, Placebo oral capsule |
| NCT03460652 KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD | ADHD | P3 | Completed | 282 | Open-label | KP415 oral capsule |
| NCT05668754 Study of SDX in Patients With Idiopathic Hypersomnia (IH) | Idiopathic Hypersomnia | P2 | Completed | 66 | RCT, Double-blind | Serdexmethylphenidate |
| NCT07125066 An Individual Patient, Open Label Study to Use ACER-001 to Treat Combined D,L-2 Hydroxyglutaric Aciduria (C-2HGA) | Combined D,L-2-hydroxyglutaric Aciduria | P1 | By Invite | 1 | Open-label | Sodium phenylbutyrate |